The purpose of this study is to assess the efficacy of a PARP inhibitor, Pamiparib, in
metastatic castration-resistant prostate cancer patients with homologous recombination
deficiency or BRCA 1 or 2 somatic/germline mutation.
This is a single arm, open-label, single center, phase II trial, assessing the efficacy of a
PARP inhibitor, Pamiparib, in 50 progressing metastatic castration-resistant prostate cancer
patients with at least one line of androgen deprivation therapy or chemotherapy at the
metastatic setting, and homologous recombination deficiency or BRCA 1 or 2 somatic or
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.